Objectives-To assess the impact of current serum fetoprotein (AFP) assays on the performance of screening for open neural tube defects and Down's syndrome. Methods-Maternal serum samples, collected between weeks 15 and 22 from 470 singleton pregnancies without neural tube defects or Down's syndrome, were assayed for AFP using an automated fluorometric immunoassay. The samples had been assayed for AFP using an in house radioimmunoassay with a lower precision ten years before. The variance of AFP using the radioimmunoassay was compared with that using the current fluorometric assay and then used to estimate the detection rates and false positive rates for neural tube defect and Down's syndrome screening. Results-Current serum AFP assays are more precise. Using a cut oV level of 2.5 multiples of the median, the false positive rate in screening for anencephaly and open spina bifida was 0.8% with the new assay compared with 2% using the previous assay. When screening for Down's syndrome, the false positive rate is reduced by about one percentage point without loss of detection. Conclusion-Improvements in the precision of maternal serum AFP measurement have led to small but useful improvements in screening for open neural tube defects and Down's syndrome. Published estimates of screening performance using such modern assays can be revised accordingly. (J Med Screen 2000;7:74-77) 
Maternal serum fetoprotein (AFP) measurement has been used as an antenatal screening test for open neural tube defects since the 1970s. 1 Since 1988, it has been used in combination with other serum markers as an antenatal screening test for Down's syndrome. 2 Recently, it has become apparent when using serum AFP measurement as a screening test for open neural tube defects, that the observed positive rate (that is the proportion of women screened with raised AFP levels) is lower than that expected on the basis of serum AFP distribution parameters estimated about 10 years ago.
A reduction in the serum AFP screen positive rate is not surprising. The eYcacy of screening using AFP measurement is deter-mined by the distribution of serum AFP in aVected and unaVected pregnancies-the less overlap in the distributions, the better the test. A reduced overlap is reflected in a reduced standard deviation, and this will probably arise due to more precise serum AFP measurement. We examine the eVect of the improvement in precision on the standard deviation of AFP at 15 to 22 weeks of pregnancy, and we estimate the resulting improvement in the performance of antenatal screening for open neural tube defects and Down's syndrome.
Methods
Estimates of the standard deviation of maternal serum AFP (and the correlation between AFP and the other serum markers) in unaffected pregnancies at any given gestational age from 15 to 22 weeks of gestation have been published. These data were based on estimating gestational age from the first day of the last menstrual period, with and without maternal weight correction, and on a biparietal diameter scan measurement (again, with and without weight correction) using data from 970 white women screened at the Homerton Hospital, London, from 1989 to 1990. [3] [4] [5] Estimates for anencephaly and open spina bifida were based on data from the UK Collaborative AFP Study (177 cases), 6 7 and those for Down's syndrome from a series from Oxford (77 cases). [3] [4] [5] They were also adjusted to take account of the method of estimating gestational age (dates or scan) and maternal weight.
Four hundred and seventy serum samples from the dataset of 970 white women with unaVected pregnancies were randomly retrieved from storage (−40°C) and thawed. AFP was measured over a period of about five weeks using an auto DELFIA AFP fluorometric immunoassay kit (DELFIA, Wallac, Finland), as in routine practice. About ten years ago, the samples had been tested using an in house assay developed in the North East Thames Radioimmunoassay Laboratory at Barts. The between batch precision of the DELFIA assay is over four times less (coeYcient of variation about 2%) than the North East Thames assay (coeYcient of variation about 10%). AFP concentrations were converted into multiples of the median (MoMs) using regression equations for gestational age based on either days from the last menstrual period (dates) or the biparietal diameter measurement from an ultrasound scan, as previously described. 7 Corrections were also made for maternal weight. 8 The variance of AFP using "dates" to estimate gestational age without maternal weight correction, using the current assay, was compared with the corresponding variance using the original AFP assay and the diVerence calculated. This diVerence was used to revise the previously published variances in unaVected, neural tube defect and Down's syndrome pregnancies. This approach was carried out in four ways with gestational age estimated by dates and scan, and with and without maternal weight correction of the MoM values.
Changes in the variance of maternal serum AFP also aVect its covariance with the other serum markers used in screening for Down's syndrome, and, as a result, the correlation coeYcients between them. The published correlations were converted into covariances (by multiplying by the two relevant standard deviations) and the diVerence used again to revise these. For example, the covariance between AFP and unconjugated oestriol (uE 3 ) using the current AFP assay, with gestational age estimated by dates and without weight correction, was compared with the corresponding covariance using the original AFP assay, and the diVerence calculated. This diVerence was then subtracted from the published covariances in unaVected and Down's syndrome pregnancies to give the revised estimates. The revised correlation coefficient between AFP and uE 3 was then calculated by taking the revised covariance and dividing it by the revised standard deviation for AFP, estimated above, and the published standard deviation for uE 3 . This was, again, carried out in four ways with gestational age estimated using dates and scan, and with and without maternal weight correction.
The detection rates and false positive rates for Down's syndrome screening were estimated for both the old and the new assay using the maternal age distribution of births in England and Wales from 1996 to 1998. 9 In the course of this study, a previous error was identified and corrected: the correlation coeYcient between uE 3 and total human chorionic gonadotrophin (hCG) in Down's syndrome pregnancies (based on scan with maternal weight adjustment) should have been −0.3520 (it was previously reported as −0.0474. 3 Table 1 shows the present and previously published estimates of the standard deviation for maternal serum AFP (log 10 MoM) in aVected and unaVected pregnancies, as well as the present correlation coeYcients between AFP and other markers. The distribution using the new assay fitted a Gaussian distribution within the truncation limits previously specified (0.3 to 3.3). The present estimate of the standard deviation of AFP is 0.1688 in unaVected pregnancies, with gestational age estimated using dates without maternal weight adjustment, compared with 0.1986 as previously published. This represents a 28% reduction in the variance. There is a similar proportional reduction in the variance with gestational age estimated using scan with maternal weight adjustment (33%).
Results
A scatter plot (figure 1) of the concentrations using the original and current AFP assays shows that there was a linear relationship between the results of the two assays. This indicates that the reduction in variance is not due to the assays diVering nonproportionally. Table 2 shows the screening performance of AFP for anencephaly and open spina bifida according to AFP cut oV level at 17 weeks of pregnancy. The mean AFP levels in aVected pregnancies were obtained from Wald et al. 10 Previously, it was estimated that 2% of women with unaVected pregnancies would have an AFP of > 2.5 MoM if gestational age is estimated by dates; now it is only 0.8%. Table 3 shows the screening performance for Down's syndrome for the double test (AFP and free human chorionic gonadotrophin (free hCG)), the triple test (AFP, total hCG and uE 3 ) and the quadruple test (triple test plus inhibin A) using the previously published means, standard deviations and correlation coeYcients, [3] [4] [5] and the present ones. Using gestational age based on scan at a 5% false positive rate, the present estimate of the detection rate is about 2 to 5 percentage points greater than that previously published. Alternatively, for a 70 percentage points detection rate, the present estimate of the false positive rate is about 1 to 2.5% lower-that is, an approximate 20% reduction in the false positive rate.
Discussion
We have confirmed that, as expected, the standard deviation of maternal serum AFP is now lower than it was 10 years ago.
The assays have improved (the AFP assay variance is 30% less), and so it is appropriate to reduce the estimate of the variance of maternal serum AFP accordingly. Screening performance for neural tube defects and Down's syndrome will, as a result of this improvement in the precision of AFP measurement, be better than earlier estimates. For example, based on the previously published parameters, we expected about 1.5% of women in our screening programme to have an AFP level of > 2. 5 MoM (for open neural tube defect screening) using scan to estimate gestational age; the present estimate is 0.5%. This is close to the rate observed in our screening programme at Barts over the last year (0.7%). The false positive rate in open neural tube defect screening is considerably reduced, and there is expected to be a modest but useful reduction in the false positive rate in Down's syndrome screening.
In screening programmes it is important to be able to predict performance and, for audit purposes, to be able to compare the observed screening performance with that expected. Expected screening performance is usually determined by statistical modelling, using the estimates of the distribution parameters (means and standard deviations and, in the case of Down's syndrome screening, the correlation coeYcients between serum markers and the age distribution of women being screened). The revised parameters and estimates of screening performance we present should be helpful in ensuring that the screening performance observed in individual screening programmes is similar to that expected. 
